Aspire BioPharma, Inc. (NASDAQ:ASBP) — Market Cap & Net Worth
Market Cap & Net Worth: Aspire BioPharma, Inc. (ASBP)
Aspire BioPharma, Inc. (NASDAQ:ASBP) has a market capitalization of $7.27 Million ($7.27 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27788 globally and #5655 in its home market, demonstrating a 6.53% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aspire BioPharma, Inc.'s stock price $6.36 by its total outstanding shares 1295234 (1.30 Million). Review Aspire BioPharma, Inc. balance sheet liabilities to assess the company's total debt and financial obligations.
Aspire BioPharma, Inc. Market Cap History: 2025 to 2026
Aspire BioPharma, Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $170.84K to $8.24 Million (0.00% CAGR).
Aspire BioPharma, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aspire BioPharma, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
27.55x
Aspire BioPharma, Inc.'s market cap is 27.55 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $170.84K | $6.20K | -$24.48 Million | 27.55x | N/A |
Competitor Companies of ASBP by Market Capitalization
Companies near Aspire BioPharma, Inc. in the global market cap rankings as of June 18, 2026.
Key companies related to Aspire BioPharma, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Aspire BioPharma, Inc. Historical Marketcap From 2025 to 2026
Between 2025 and today, Aspire BioPharma, Inc.'s market cap moved from $170.84K to $ 8.24 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $8.24 Million | +4721.83% |
| 2025 | $170.84K | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Aspire BioPharma, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.27 Million USD |
| MoneyControl | $7.27 Million USD |
| MarketWatch | $7.27 Million USD |
| marketcap.company | $7.27 Million USD |
| Reuters | $7.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aspire BioPharma, Inc.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually admi… Read more